Entrada Therapeutics Inc (TRDA) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Entrada Therapeutics Inc   (NASDAQ: TRDA)


Entrada Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Entrada Therapeutics Inc 's ROA in the second quarter of 2026?
Entrada Therapeutics Inc achieved a return on average assets (ROA) of 9.51 % in its second quarter of 2026, this is above TRDA's average return on assets of 4.09%.
Entrada Therapeutics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $356 million

ROA has improved compared to 8.57% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 103 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 726, from total ROA ranking in the first quarter of 2026 at 2974.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -33.4 % -31.03 % -16.69 % -13.82 % -10.76 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 34 34 -1 -67 -64
Return On Assets (TTM) 9.51 % 8.57 % -0.21 % -14.86 % -13.8 %
TRDA's Total Ranking # 726 # 2974 # 3408 # 3383 # 692
Total Assets (TTM) in million 299 336 377 413 449
Seq. Total Assets Change -10.92 % -11.09 % -8.6 % -8 % -7.75 %
Seq. Net Income Change - - - - -

TRDA's 5 Years Annual ROA >> Back to TRDA Management Effectiveness >> Compare TRDA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 41
Sector # 104
Overall # 632

Return On Assets Statistics
High Average Low
83.12 %
4.09 %
-33.22 %
(Mar 31 2022)   (Dec 31 2022)



  News about Entrada Therapeutics Inc Return on Assets ROA

Entrada Therapeutics Launches ELEVATE-45-201 Study, Pioneering Exon Skipping Strategies in Duchenne Muscular Dystrophy Treatment

In a significant advancement for the treatment of Duchenne Muscular Dystrophy (DMD), Entrada Therapeutics has received authorization from the United Kingdom s regulatory authorities to initiate the ELEVATE-45-201 study. This Phase 1/2 Multiple Ascending Dose clinical trial will assess ENTR-601-45, a promising investigational drug designed for individuals living with DMD who are amenable to exon 45 skipping. This authorization comes at a time of heightened urgency to discover effective therapeutic strategies for a condition that has long stymied conventional treatments.DMD is a devastating genetic disorder primarily affecting young males and characterized by relentless muscle degeneration and weakness. The underlying cause of DMD lies in mutations in the dystrophin gene, which results in the absence of dystrophin—a crucial protein that serves to protect muscle fibers from damage during contractions. Traditionally, this absence accelerates muscle deterioration, leading to significant functional impairments and a drastically reduced lifespan, with many patients experiencing loss of ambulation by their late teens and succumbing to cardiac and respiratory complications in early adulthood.



Financial Statements
Entrada Therapeutics Inc 's Assets $ 299 million TRDA's Balance sheet
Entrada Therapeutics Inc 's Income $ 0 million Quarterly TRDA's Income Statement
TRDA's Income by Division See TRDA's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -16.69 % 17.36 % 71.12 % -26.25 % -
Total Assets in million 377 453 386 226 306
Y / Y Net Income Change - 2359.71 % - - -
Net Income in million -1 132 5 -95 -51
Annual Return On Assets -0.24 % 29.17 % 1.39 % -41.95 % -16.73 %

TRDA's 5 Years Annual ROA >> Back to TRDA Management Effectiveness >> Compare TRDA ROA to its Competitors



More Return On Assets Ratios
TRDA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TRDA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TRDA's Competitors
Subscribers only: Roa for Entrada Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for TRDA's Customers

You may also want to know
TRDA's Roi TRDA's Inventory Turnover Ratio TRDA's Growth Rates TRDA's Dividend Comparisons
TRDA's Profitability Ratios TRDA's Asset Turnover Ratio TRDA's Dividend Growth
TRDA's Roe TRDA's Valuation Ratios TRDA's Financial Strength Ratios TRDA's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %
Standard Biotools Inc   14.31 %
Arcutis Biotherapeutics Inc   14.23 %
Harmony Biosciences Holdings inc   14.15 %
Biolife Solutions Inc   14.09 %

Date modified: 2026-09-08T22:40:06+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.